Pulse Biosciences, Inc

Thank you for standing by. Hello and welcome to the Pulse Biosciences second quarter 2025 earnings conference call. Please note that this call is being recorded. I would now like to hand the call over to Tripp Taylor.

Sir, please go ahead. Thank you, operator.

Before we begin, I would like to inform you that comments and responses to your questions during today's call reflect management's views as of today, August 12, 2025 only, and will include forward-looking statements and opinion statements, including predictions, estimates, plans, expectations, and other similar information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued earlier today and in our filings with the US Securities and Exchange Commission. Our SEC filings can be found on our website or the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We disclaim any obligation to update or revise these forward-looking statements. We will also discuss certain non-GAAP financial measures. Disclosures regarding these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will be available for audio replay on our website at PulseBiosciences.com in the News and Events section on our Investor Relations page. With that, I would now like to turn the call over to Co-Chair of the Board and Chief Executive Officer, Paul LaViolette.